| CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma IS Nijhof, T Casneuf, J Van Velzen, B van Kessel, AE Axel, K Syed, ... Blood, The Journal of the American Society of Hematology 128 (7), 959-970, 2016 | 373 | 2016 |
| Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab IS Nijhof, RWJ Groen, HM Lokhorst, B Van Kessel, AC Bloem, ... Leukemia 29 (10), 2039-2049, 2015 | 293 | 2015 |
| Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab J Krejcik, KA Frerichs, IS Nijhof, B van Kessel, JF van Velzen, AC Bloem, ... Clinical cancer research 23 (24), 7498-7511, 2017 | 176 | 2017 |
| Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma RWJ Groen, WA Noort, RA Raymakers, HJ Prins, L Aalders, FM Hofhuis, ... Blood, The Journal of the American Society of Hematology 120 (3), e9-e16, 2012 | 155 | 2012 |
| Multicolor flow cytometry for evaluation of platelet surface antigens and activation markers JF van Velzen, BAP Laros-van Gorkom, GAM Pop, WL van Heerde Thrombosis research 130 (1), 92-98, 2012 | 126 | 2012 |
| The inflammasome and caspase-1 activation: a new mechanism underlying increased inflammatory activity in human visceral adipose tissue TB Koenen, R Stienstra, LJ Van Tits, LAB Joosten, JF Van Velzen, ... Endocrinology 152 (10), 3769-3778, 2011 | 123 | 2011 |
| GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation M Kox, JF van Velzen, JC Pompe, CW Hoedemaekers, ... Biochemical pharmacology 78 (7), 863-872, 2009 | 102 | 2009 |
| Establishing human leukemia xenograft mouse models by implanting human bone marrow–like scaffold-based niches A Antonelli, WA Noort, J Jaques, B de Boer, R de Jong-Korlaar, ... Blood, The Journal of the American Society of Hematology 128 (25), 2949-2959, 2016 | 90 | 2016 |
| Lymphocyte maintenance during healthy aging requires no substantial alterations in cellular turnover L Westera, V van Hoeven, J Drylewicz, G Spierenburg, JF van Velzen, ... Aging cell 14 (2), 219-227, 2015 | 89 | 2015 |
| Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy Q De Mast, PG De Groot, WL Van Heerde, M Roestenberg, JF Van Velzen, ... British journal of haematology 151 (5), 495-503, 2010 | 64 | 2010 |
| Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients KA Frerichs, PWC Bosman, JF van Velzen, PLA Fraaij, MPG Koopmans, ... Haematologica 105 (6), e302, 2020 | 62 | 2020 |
| Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma IS Nijhof, LE Franssen, MD Levin, GMJ Bos, A Broijl, SK Klein, HR Koene, ... Blood, The Journal of the American Society of Hematology 128 (19), 2297-2306, 2016 | 62 | 2016 |
| Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide … LE Franssen, IS Nijhof, CC Bjorklund, H Chiu, R Doorn, J Van Velzen, ... Oncotarget 9 (74), 34009, 2018 | 24 | 2018 |
| Expression levels of CD38 and complement inhibitory proteins CD55 and CD59 predict response to daratumumab in multiple myeloma I Nijhof, A Axel, T Casneuf, T Mutis, A Bloem, J Van Velzen, B Van Kessel, ... Haematologica 100, 175-176, 2015 | 13 | 2015 |
| Inability of a monoclonal anti‐light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry JF van Velzen, D van den Blink, AC Bloem Cytometry Part B: Clinical Cytometry 84 (1), 30-32, 2013 | 11 | 2013 |
| Aberrant hepatic lipid storage and metabolism in canine portosystemic shunts L Van den Bossche, VAC Schoonenberg, IA Burgener, LC Penning, ... Plos one 12 (10), e0186491, 2017 | 10 | 2017 |
| Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of refractory patient-derived multiple myeloma cells, growing in a novel humanized mouse MM model WA Noort, RWJ Groen, R Raymakers, L Aalders, FM Hofhuis, ... Blood 120 (21), 940, 2012 | 8 | 2012 |
| CD38 levels are associated with response and complement inhibitors contribute to resistance in myeloma patients treated with daratumumab IS Nijhof, T Casneuf, J Van Velzen, B van Kessel, AE Axel, K Syed, ... Blood 128, 959-70, 2016 | 6 | 2016 |
| A “No‐Touch” Antibody‐Staining Method of Adherent Cells for High‐Throughput Flow Cytometry in 384‐Well Microplate Format for Cell‐Based Drug Library Screening AM Cornel, CL Szanto, NP van Til, JF van Velzen, JJ Boelens, S Nierkens Cytometry Part A 97 (8), 845-851, 2020 | 5 | 2020 |
| Phase 1/2 trial of lenalidomide in combination with cyclophosphamide and prednisone (REP) in patients with lenalidomide-refractory multiple myeloma (REPEAT-study) IS Nijhof, S Zweegman, MD Levin, HR Koene, A Beeker, AC Bloem, ... Blood 122 (21), 287, 2013 | 5 | 2013 |
